These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10338045)

  • 1. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.
    del Cañizo C; Lopez N; Caballero D; Fernandez E; Brufau A; Vazquez L; Mateos V; Gutierrez N; San Miguel JF
    Bone Marrow Transplant; 1999 May; 23(9):901-5. PubMed ID: 10338045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery.
    del Cañizo MC; Lopez N; Vazquez L; Fernandez ME; Ana B; Caballero MD; Amigo ML; Mateos MV; Gutierrez N; San Migue JF
    Haematologica; 1999 Jun; 84(6):511-6. PubMed ID: 10366794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
    Novitzky N; Mohamed R
    Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of chemotherapy on hematopoietic microenvironment and effect of autologous bone marrow stromal cell infusion on the recovery of hematopoiesis after chemotherapy].
    Liu J; Ji S; Zhou L; Chen H
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):341-3. PubMed ID: 11877093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
    Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
    Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients.
    Soligo DA; Lambertenghi Deliliers G; Servida F; Quirici N; Campiglio S; Tagliaferri E; Oriani A; Romitti L; Della Volpe A; Annaloro C
    Bone Marrow Transplant; 1998 Jan; 21(1):15-22. PubMed ID: 9486489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant.
    Selleri C; Maciejewski JP; De Rosa G; Raiola A; Risitano AM; Picardi M; Pezzullo L; Luciano L; Ricci P; Varriale G; Della Cioppa P; Del Vecchio L; Rotoli B
    Bone Marrow Transplant; 1999 May; 23(10):1029-37. PubMed ID: 10373069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation.
    Domenech J; Cartron G; Clement N; Estienne MH; Herault O; Truglio D; Benboubker L; Roingeard F; Desbois I; Colombat P; Binet C
    Bone Marrow Transplant; 2002 Apr; 29(7):557-62. PubMed ID: 11979303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of chemotherapy on hematopoietic stem cells in peripheral blood].
    Nieto MJ; Cañizo C; Corral M; Almeida J; San Miguel J
    Sangre (Barc); 1996 Feb; 41(1):29-35. PubMed ID: 8779031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
    J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation.
    Mahmut N; Katayama Y; Takenaka K; Teshima T; Ohno Y; Imajyo K; Hara M; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Int J Hematol; 1999 Jan; 69(1):36-42. PubMed ID: 10641441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E; Mahlamäki E; Nousiainen T
    Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation.
    Tarella C; Gavarotti P; Caracciolo D; Locatelli F; Falda M; Paolino F; Lovisone E; Sormano E; Tassi V; Urgesi A
    Haematologica; 1990; 75 Suppl 1():90-4. PubMed ID: 1972137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors.
    López-Holgado N; Pata C; Villarón E; Sánchez-Guijo F; Alberca M; Martín A; Corral M; Sánchez-Abarca I; Pérez-Simón JA; San Miguel JF; del Cañizo MC
    Haematologica; 2005 Mar; 90(3):353-9. PubMed ID: 15749668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.